اگلا

آٹو پلے

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

0 مناظر • 07/14/23
بانٹیں
ایمبیڈ
administrator
administrator
سبسکرائبرز
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

مزید دکھائیں
0 تبصرے sort ترتیب دیں
فیس بک کے تبصرے

اگلا

آٹو پلے